| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
|
Gastroenterology
|
2003
|
2.97
|
|
2
|
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
|
Clin Pharmacol Ther
|
2002
|
2.01
|
|
3
|
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
|
Clin Pharmacol Ther
|
2004
|
1.99
|
|
4
|
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology.
|
Basic Clin Pharmacol Toxicol
|
2010
|
1.96
|
|
5
|
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.
|
Pharmacogenetics
|
2002
|
1.75
|
|
6
|
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
|
Clin Pharmacol Ther
|
2002
|
1.58
|
|
7
|
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene.
|
Pharmacogenetics
|
2003
|
1.51
|
|
8
|
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.
|
Brain Pathol
|
2007
|
1.45
|
|
9
|
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
|
Antimicrob Agents Chemother
|
2005
|
1.42
|
|
10
|
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.
|
Curr Alzheimer Res
|
2004
|
1.42
|
|
11
|
Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.40
|
|
12
|
CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis.
|
Carcinogenesis
|
2003
|
1.28
|
|
13
|
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
|
Clin Pharmacol Ther
|
2002
|
1.23
|
|
14
|
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation.
|
Carcinogenesis
|
2002
|
1.23
|
|
15
|
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
|
Eur J Clin Pharmacol
|
2003
|
1.20
|
|
16
|
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
|
Pharmacogenet Genomics
|
2008
|
1.18
|
|
17
|
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.
|
J Clin Psychiatry
|
2010
|
1.16
|
|
18
|
Educating European (junior) doctors for safe prescribing.
|
Basic Clin Pharmacol Toxicol
|
2007
|
1.15
|
|
19
|
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation.
|
Drug Metab Dispos
|
2005
|
1.14
|
|
20
|
CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls.
|
Int J Cancer
|
2003
|
1.13
|
|
21
|
The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart.
|
J Histochem Cytochem
|
2005
|
1.10
|
|
22
|
[Hypoglycemic risk of insulinotropic drugs].
|
Med Monatsschr Pharm
|
2009
|
1.05
|
|
23
|
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.
|
Clin Pharmacol Ther
|
2004
|
1.05
|
|
24
|
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States).
|
Cancer Causes Control
|
2003
|
1.04
|
|
25
|
A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
1.04
|
|
26
|
Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients.
|
PLoS One
|
2011
|
1.02
|
|
27
|
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.
|
Pharmacogenet Genomics
|
2009
|
1.02
|
|
28
|
Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379.
|
Mol Pharmacol
|
2011
|
1.01
|
|
29
|
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.
|
Br J Clin Pharmacol
|
2002
|
0.99
|
|
30
|
Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
|
Clin Pharmacol Ther
|
2006
|
0.99
|
|
31
|
miRNAs as mediators of drug resistance.
|
Epigenomics
|
2012
|
0.98
|
|
32
|
Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study.
|
Mutat Res
|
2005
|
0.94
|
|
33
|
Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis.
|
Genet Med
|
2007
|
0.94
|
|
34
|
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
|
Expert Opin Drug Metab Toxicol
|
2014
|
0.94
|
|
35
|
High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma.
|
Cancer Lett
|
2004
|
0.91
|
|
36
|
OpenVigil--free eyeballs on AERS pharmacovigilance data.
|
Nat Biotechnol
|
2012
|
0.90
|
|
37
|
Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart.
|
Am J Pathol
|
2003
|
0.90
|
|
38
|
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
|
Pharmacogenet Genomics
|
2012
|
0.90
|
|
39
|
Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.
|
Pharmacogenetics
|
2004
|
0.90
|
|
40
|
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
|
Eur J Clin Pharmacol
|
2011
|
0.90
|
|
41
|
Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
|
Ther Drug Monit
|
2015
|
0.89
|
|
42
|
Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy.
|
J Histochem Cytochem
|
2002
|
0.89
|
|
43
|
Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
|
BMC Cancer
|
2013
|
0.89
|
|
44
|
Association of metabolic gene polymorphisms with tobacco consumption in healthy controls.
|
Int J Cancer
|
2004
|
0.89
|
|
45
|
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis.
|
J Clin Psychopharmacol
|
2004
|
0.87
|
|
46
|
Antimicrobial peptides and proteins of the horse--insights into a well-armed organism.
|
Vet Res
|
2011
|
0.86
|
|
47
|
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients.
|
Neuropsychobiology
|
2004
|
0.85
|
|
48
|
Endothelial NO synthase polymorphisms and postural tachycardia syndrome.
|
Hypertension
|
2005
|
0.85
|
|
49
|
Endothelial nitric oxide synthase Glu(298)-->Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample.
|
Clin Sci (Lond)
|
2005
|
0.84
|
|
50
|
MicroRNAs and their relevance to ABC transporters.
|
Br J Clin Pharmacol
|
2014
|
0.83
|
|
51
|
Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample.
|
Pharmacogenet Genomics
|
2005
|
0.83
|
|
52
|
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).
|
Clin Cancer Res
|
2013
|
0.82
|
|
53
|
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
|
Br J Clin Pharmacol
|
2006
|
0.82
|
|
54
|
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
|
Basic Clin Pharmacol Toxicol
|
2010
|
0.82
|
|
55
|
Pharmacogenetics-based new therapeutic concepts.
|
Drug Metab Rev
|
2004
|
0.81
|
|
56
|
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus.
|
Pharmacogenetics
|
2002
|
0.81
|
|
57
|
Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method.
|
Chem Biol Interact
|
2011
|
0.81
|
|
58
|
Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation.
|
J Biol Chem
|
2012
|
0.81
|
|
59
|
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.
|
Pharmacogenet Genomics
|
2011
|
0.81
|
|
60
|
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity.
|
Pharmacogenomics
|
2009
|
0.81
|
|
61
|
Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010.
|
Pharmacogenomics
|
2011
|
0.80
|
|
62
|
Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample.
|
J Hypertens
|
2005
|
0.80
|
|
63
|
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
|
Cancer Lett
|
2005
|
0.80
|
|
64
|
Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
|
Clin Ther
|
2010
|
0.79
|
|
65
|
Association between the N-acetylation genetic polymorphism and bronchial asthma.
|
Br J Clin Pharmacol
|
2002
|
0.79
|
|
66
|
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.
|
Pharmacogenet Genomics
|
2016
|
0.79
|
|
67
|
Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes.
|
Pharmacogenet Genomics
|
2007
|
0.79
|
|
68
|
The promises of personalized medicine.
|
Eur J Clin Pharmacol
|
2010
|
0.78
|
|
69
|
Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients.
|
Epilepsia
|
2008
|
0.78
|
|
70
|
Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition.
|
Clin Pharmacol Ther
|
2002
|
0.78
|
|
71
|
Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379.
|
Pharmacogenet Genomics
|
2014
|
0.78
|
|
72
|
Influence of an insertion variant in the 5'UTR of the endothelin-1 gene on orthostatic intolerance.
|
Am J Med Sci
|
2005
|
0.77
|
|
73
|
Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?
|
J Clin Psychopharmacol
|
2005
|
0.77
|
|
74
|
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
|
Inflamm Bowel Dis
|
2010
|
0.77
|
|
75
|
Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma.
|
Eur J Clin Pharmacol
|
2003
|
0.77
|
|
76
|
Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.
|
Liver Int
|
2006
|
0.76
|
|
77
|
Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
|
Eur J Clin Pharmacol
|
2004
|
0.76
|
|
78
|
Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation.
|
Pharmacogenomics
|
2009
|
0.76
|
|
79
|
Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences.
|
J Mol Med (Berl)
|
2003
|
0.75
|
|
80
|
Highlights from the latest articles in breast cancer pharmacogenomics.
|
Pharmacogenomics
|
2012
|
0.75
|
|
81
|
Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
|
PLoS One
|
2017
|
0.75
|
|
82
|
Correspondence (reply): In Reply.
|
Dtsch Arztebl Int
|
2013
|
0.75
|
|
83
|
Opportunities and limitations: the value of pharmacogenetics in clinical practice.
|
Br J Clin Pharmacol
|
2014
|
0.75
|
|
84
|
Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians.
|
Drug Metab Dispos
|
2014
|
0.75
|
|
85
|
Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis.
|
Clin Chem
|
2004
|
0.75
|
|
86
|
A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis.
|
Thromb Haemost
|
2005
|
0.75
|
|
87
|
5th Anniversary meeting of the European Research Network Pharmacogenetics/Pharmacogenomics. 8-9 December 2011, Utrecht, The Netherlands.
|
Pharmacogenomics
|
2012
|
0.75
|
|
88
|
Pharmacogenomics in acute coronary syndrome.
|
Expert Opin Pharmacother
|
2008
|
0.75
|
|
89
|
Regulation's threat to research. A UK problem.
|
BMJ
|
2008
|
0.75
|
|
90
|
Conference Scene: Pharmacogenomic highlights of the DGPT Annual Congress.
|
Pharmacogenomics
|
2012
|
0.75
|